TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03023423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab 1200 mg intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab 1200 mg intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive daratumumab 16 mg/kg intravenously.
Study: NCT03454659

Intervention type: PROCEDURE
Intervention: Craniotomy
Description: Extracting the part of the sculpt

Intervention type: PROCEDURE
Intervention: Craniotomy
Description: Extracting the part of the sculpt
Study: NCT01498783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil, bolus dose of 500 mg/m\^2 given weekly for 4 weeks followed by a two week rest period equals one cycle (6 weeks). Therapy may continue for up to 16 cycles (about 2 years).
Study: NCT05092698

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D (cholecalciferol)
Description: Patients will receive 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of cholecalciferol weekly and 5,000 IU of cholecalciferol (two drops) daily until discharge or death.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Herbal oil
Description: Patients will receive 45 ml of herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of pure herbal oil weekly and two drops of herbal oil daily until discharge or death.
Study: NCT01084993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bivalirudin
Description: Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: 70 U/kg
Study: NCT05612646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: The patients assigned to the experimental group received acupoint massage designed to improve constipation for 7 days during hospitalization. The selection of acupoints in this study includes Tianshu (double) (Tianshu, ST25: Stomach Meridian 25, the 25th point of the stomach meridian), Zhongwan (single) (Zhongwan CV12: Conception Vessel 12, the 12th point of the Ren meridian) ), Qihai Point (Single) (Qihai CV6: Meridian Vessel 6 Renmai 6th point) 3 points.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: routine nursing and fake acupressure
Description: control groups: receiving routine nursing and fake acupressure to improve constipation for 7 days during hospitalization.
Study: NCT02930252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Niti-S Biliary ComVi Stent
Description: Endoscopic placement of biliary fully covered metal stents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Niti-S stent (D type)
Description: Endoscopic placement of biliary uncovered metal stent
Study: NCT04431219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIS1
Description: LIS1 is an induction treatment on top of maintenance immunosuppressive regimen. All patients from AD and TD cohort will receive the conventional immunosuppressive regimen: tacrolimus (0.2 mg/kg) / mycophenolic acid (MMF, 2x1000 mg) / prednisone (20 mg from day 2). This conventional treatment should be started and monitored for all patients independently of their participation in the clinical trial. Methylprednisolone 500 mg / 100 mL saline / 30 minutes will be administered before reperfusion during the surgery and on post operation day 1 just before LIS1 administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIS1
Description: LIS1 is an induction treatment on top of maintenance immunosuppressive regimen. All patients from AD and TD cohort will receive the conventional immunosuppressive regimen: tacrolimus (0.2 mg/kg) / mycophenolic acid (MMF, 2x1000 mg) / prednisone (20 mg from day 2). This conventional treatment should be started and monitored for all patients independently of their participation in the clinical trial. Methylprednisolone 500 mg / 100 mL saline / 30 minutes will be administered before reperfusion during the surgery and on post operation day 1 just before LIS1 administration.
Study: NCT00352378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine
Description: Patients will be randomized to receive regimen A (AC) and regimen B(TX),preoperatively as follows:~Regimen A (AC): Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1. Regimen B(TX): Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine
Description: Patients will be randomized to receive regimen A (AC) and regimen B(TX),preoperatively as follows:~Regimen A (AC): Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1. Regimen B(TX): Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14
Study: NCT04141722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overnight sleep
Description: Participant sent home to sleep overnight wearing PSG.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wake
Description: Participant sent to go about normal daily routine, instructed not to nap, drink caffeine, or engage in strenuous exercise.
Study: NCT00764270

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: R-alpha lipoic acid
Description: 300 mg R-alpha lipoic acid or placebo twice daily for 12 weeks, followed by a washout period of 12 weeks, followed by another treatment phase of the other treatment placebo or 300 mg R-alpha-lipoic acid for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: R-alpha lipoic acid
Description: 300 mg R-alpha lipoic acid or placebo twice daily for 12 weeks, followed by a washout period of 12 weeks, followed by another treatment phase of the other treatment placebo or 300 mg R-alpha-lipoic acid for 12 weeks
Study: NCT00428337

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP-1233
Description: DNA-HIV-recombinant vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP-1233
Description: DNA-HIV-recombinant vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-mBN32
Description: HIV-recombinant viral vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-mBN32
Description: HIV-recombinant viral vaccine
Study: NCT01198847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary, physical activity and sleeping
Description: The intervention in the present study will be delivered through sessions aiming at developing healthy lifestyle habits regarding physical activity, food intake and regular sleeping habits for parents and children. These sessions will be performed face to face by trained health care workers and carried out in the welfare centres with the parent/s. Children will not be approached directly in the present study. All families will meet with their coach/facilitator during at least 12 times (including start and final evaluation meeting) until the children reach 6 years of age (such as school age). However extra effort (as boosting sessions) will be made if growth records show an increased BMI (weight induced meetings). The parents are also encouraged to keep contact with their coach either by phone or e-mail as often as they feel needed.~The Low intensity arm will only receive written information and no direct face to face support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary, physical activity and sleeping
Description: The intervention in the present study will be delivered through sessions aiming at developing healthy lifestyle habits regarding physical activity, food intake and regular sleeping habits for parents and children. These sessions will be performed face to face by trained health care workers and carried out in the welfare centres with the parent/s. Children will not be approached directly in the present study. All families will meet with their coach/facilitator during at least 12 times (including start and final evaluation meeting) until the children reach 6 years of age (such as school age). However extra effort (as boosting sessions) will be made if growth records show an increased BMI (weight induced meetings). The parents are also encouraged to keep contact with their coach either by phone or e-mail as often as they feel needed.~The Low intensity arm will only receive written information and no direct face to face support
Study: NCT00101998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvimopan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvimopan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvimopan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02171247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovue 370
Description: Isovue 370 is a contrast agent with increased iodine concentration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visipaque 320
Description: Visipaque 320 is standard protocol.
Study: NCT02592707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satoreotide tetraxetan
Description: Satoreotide tetraxetan administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino acid solution
Description: Given as an auxiliary product the day of the IMP infusion for safety reasons to protect the renal function.~Centres can use their established amino acid infusion or Ipsen amino acid solution (auxiliary medical product OPS301)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiemetic
Description: To counteract the known side effects of the amino acid infusion, such as nausea, dexamethasone (antiemetic) and as-required ondansetron will be administered 15 to 30 minutes before the start of the amino acid infusion (unless there are contraindications for these drugs).
Study: NCT03190629

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flux hemodialysis
Description: Hemodialysis treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Hemodialysis treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On line-hemodiafiltration
Description: Post-dilution on line-hemodiafiltration treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Post-dilution on line-hemodiafiltration treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care), with automatic adjustment of the substitution fluid flow rate for maximising substitution volume while simultaneously avoiding haemoconcentration and filter clotting.
Study: NCT04295850

Intervention type: DRUG
Intervention: Aspirin 81 mg
Description: Aspirin 81mg daily PO
Study: NCT00581841

Intervention type: OTHER
Intervention: Gait analysis, knee x-ray, and knee MRI
Description: Gait analysis, knee x-rays, and knee MRIs will be done twice for each participant, 1 week apart.
Study: NCT04038671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activated Carbon Cloth Dressing
Description: Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Knitted Cellulose Acetate Mesh
Description: Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial Alginate Dressing with Silver
Description: Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
Study: NCT04124471

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Open-ended semi-structured interviews
Description: Semi-structured interviews will explore such key constructs as knowledge/belief about OSAS and PAP therapy, routines and resources that promote or limit PAP use, barriers, self-efficacy, and communication and attitudes about PAP. The interviews will be performed with the parent and that they will be audio-recorded.
Study: NCT02712190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency non-invasive ventilation
Description: Comparison of 2 different settings of HF-NIV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency non-invasive ventilation
Description: Comparison of 2 different settings of HF-NIV
Study: NCT05708313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification
Description: Participants will undergo an exercise program designed by AHH
Study: NCT01991925

Intervention type: OTHER
Intervention: Interviews, questionaires, RAND-modified delphi method round
Description: phase 1: RAND-modified delphi method round with experts in hereditary haemochromatosis phase 2: patient interviews, questionnaires and focus group interviews
Study: NCT03216941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: study medications were packaged in identical color-coded boxes. first dosage included either 10 mg of olanzapine, or 10 mg of ketamine Dosages were chosen based on previous studies After the initial dose, no additional dosis were allowed if supplemental medication eas needed according to clinician judgment the subject will be immediately removed from the study.~All subjects will be assessed 1 hour, 2 hours, 4 hours, 6 hours and 12 hours after t he first administration of the medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: study medications were packaged in identical color-coded boxes. first dosage included either 10 mg of olanzapine, or 10 mg of ketamine Dosages were chosen based on previous studies After the initial dose, no additional dosis were allowed if supplemental medication eas needed according to clinician judgment the subject will be immediately removed from the study.~All subjects will be assessed 1 hour, 2 hours, 4 hours, 6 hours and 12 hours after t he first administration of the medication.
Study: NCT00960505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternate day fasting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie restriction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Study: NCT04633785

Intervention type: OTHER
Intervention: No Intervention
Description: There are no interventions in this study. The mercury sphygmomanometer and the wrist sphygmomanometer will be used in this study to collect blood pressure values from the study subjects.
Study: NCT02325583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% Glucose
Description: ORAL 30% GLUCOSE 0,5-2 ML

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: INTRAVENOUS 0.1 MG/KG MIDAZOLAM
Study: NCT03025997

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active yoghurt
Description: Active yoghurt (containing encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yoghurt
Description: Placebo yoghurt (containing non-encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
Study: NCT04106453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: navigated microwave ablation
Description: the laparoscopic microwave ablation in the pig liver is performed with the CasOne-Spot system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided navigation
Description: the laparoscopic microwave ablation iin the pic liver is performed with ultrasound guidance
Study: NCT01216059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Text message to cell phone
Description: Subjects will receive a daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study
Study: NCT03751553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obsteric gel(k-Y jelly)
Description: A sterile obstetric gel( K-Y Jelly 82GM; manufactured by Johnson\&amp; Johnson) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that have purely physical activity. Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child manually or using the sterile obstetric gel applicator without any manipulation or massage.
Study: NCT01734473

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein protein
Description: Amount provided is based on the fat-free mass of subject

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein protein + carbohydrates
Description: Amount provided is based on the fat-free mass of subject

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein protein + leucine
Description: Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein protein + carbohydrates + leucine
Description: Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4 levels of hydrolyzed casein protein + carbohydrates
Description: Amount provided is based on the fat-free mass of subject. The 4 levels are: 0, 0.02, 0.05, 0.15 g casein protein/kg fat free mass/hr. The ratio between protein and carbohydrates is fixed.
Study: NCT01878383

Intervention type: DEVICE
Intervention: Genexpert assay

Intervention type: DEVICE
Intervention: Genexpert assay
Study: NCT04590950

Intervention type: OTHER
Intervention: Non interventional study
Description: Non interventional study
Study: NCT02628964

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: e-cigarettes
Description: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: e-cigarettes
Description: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.
Study: NCT00552513

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Early Coronary Intervention
Description: Perform coronary angiography and intervention (either percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\] surgery) as soon as possible (and within 24 hours of randomisation).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Delayed Coronary Intervention
Description: Perform coronary angiography and intervention (either percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\] surgery) any time after 36 hours after randomisation.
Study: NCT00675038

Intervention type: PROCEDURE
Intervention: Liver Biopsy and MRI T2* MRI
Description: Evaluation of iron overload with liver biopsy vs. MRI T2\* MRI
Study: NCT02720185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 100mg oral once daily dasatinib taken for 7-10 days up to the day prior to planned surgery or research biopsy (neoadjuvant chemotherapy group)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01865500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 4 mg
Description: It will be evaluated at baseline, 24 h, 48 h and before discharge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 4 mg
Description: It will be evaluated at baseline, 24 h, 48 h and before discharge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 8 mg
Description: Baseline FEV1 and before discharge FEV1 were evaluated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 8 mg
Description: Baseline FEV1 and before discharge FEV1 were evaluated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metil prednisolone
Study: NCT03466879

Intervention type: DEVICE
Intervention: SYNUS Pain Relief device
Description: SYNUS Pain Relief is a handheld micro-current TENS device used for the temporary relief of sinus pain.
Study: NCT05558800

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Implant placement
Description: Implant placement with different surface types

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Implant placement with different surface types

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Implant placement with different surface types

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Implant placement with different surface types
Study: NCT01608516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-RGD PET/CT
Description: 200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images centred on the carotid area acquired